-
Scientists Use Pharmacogenomics to Provide Personalized Medicine
20 Dec 2025 15:13 GMT
… variety of medications. These … Pharmacogenomics panels
Scientists have developed pharmacogenomics … drug pharmacokinetics and pharmacodynamics.4
Cardiovascular pharmacogenomics
Cardiovascular disease treatment … (heart attack), atrial fibrillation, and thrombosis …
-
Periodontitis: A Diabetes Modifier in Older Atrial Fibrillation Patients
19 Dec 2025 14:47 GMT
… synergistic approach to treating patients with diabetes and atrial fibrillation, incorporating dental … results that could ultimately transform treatment protocols and improve health … care—one that champions comprehensive treatment and emphasizes the vital …
-
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
18 Dec 2025 12:39 GMT
… . Food and Drug Administration (FDA) has granted … reshaped how we treat atrial fibrillation, but its … development of its nPulse technology for use in the treatment of atrial fibrillation … treatment option or a superior option for treating atrial fibrillation …
-
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
19 Dec 2025 21:00 GMT
… S. Food and Drug Administration (FDA) has approved MYQORZO … ongoing monitoring requirements
Pharmacies must be … concomitant medications prior to and during MYQORZO treatment. … of also developing cardiovascular complications including atrial fibrillation, stroke …
-
<![CDATA[The 5 Most Impactful FDA Approvals of 2025]]>
19 Dec 2025 16:23 GMT
… a standalone treatment or adjunct to medication. It is … PharmD, BCPS, pharmacy director of Drug Use Policy and … develop an opioid use disorder after receiving a prescription opiate to treat … embolism in patients with atrial fibrillation. For the first …
-
Pulse Biosciences wins FDA approval to begin PFA catheter study
19 Dec 2025 05:31 GMT
… system to treat drug-resistant paroxysmal, or intermittent, atrial fibrillation.
The company has developed technology … system in March and expects FDA approval next year.
Pulse Biosciences …
-
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
17 Dec 2025 23:39 GMT
… and CEO, Milestone Pharmaceuticals.
Proven Nasal Drug Delivery Platforms
Aptar’s … development for the treatment of symptomatic episodic attacks associated with atrial fibrillation … KEYWORD: GENERAL HEALTH FDA HEALTH PHARMACEUTICAL CARDIOLOGY
SOURCE: Aptar …
-
Huxley Medical Announces Commercial Launch of FDA-Cleared Central Sleep Apnea Detection and Appointment of Medical Director of Sleep Medicine
17 Dec 2025 15:57 GMT
… .S. Food and Drug Administration (FDA) 510(k) clearance … as heart failure and atrial fibrillation," said Rami Khayat … it can significantly alter treatment decisions. This is an … proprietary expertise in biosensor development, physiological signal analysis, …
-
6 Popular Supplements That May Have Hidden Dangers
19 Dec 2025 06:24 GMT
Your body needs vitamin D along with calcium to build bones and keep them healthy, and to support immune health, muscles, and brain cells. Some research has also found that vitamin D may prevent diseases like cancer and osteoporosis.[1]
Food sources of …
-
What 3 ASC leaders have said about cardiology’s growing outpatient boom
19 Dec 2025 02:44 GMT
… underserved rural patient base. Atrial fibrillation and heart failure are … coincided with the development of a focused atrial fibrillation clinic model … to improve access and standardization of guideline based treatment …
About
© 1995-2025